

29<sup>th</sup> May, 2023

**BSE Limited**  
P.J. Towers, Dalal Street, Fort,  
Mumbai- 400 001  
BSE scrip code: 543635

**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051  
NSE symbol: PPLPHARMA

**Sub: SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015**  
**(‘Listing Regulations’) - Transcript of Conference Call with Investors/Analysts**

Dear Sir / Madam,

Further to our intimation made earlier and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the Conference Call held on 25<sup>th</sup> May, 2023 on the financial results (Standalone and Consolidated) of the Company for the quarter and year ended 31<sup>st</sup> March, 2023.

The transcript of the said conference call is also hosted on the website of the Company at <https://www.piramal.com/investor/piramal-pharma-limited/financial-reports/investor-calls/>

Kindly take the above on record.

Thanking you,

Yours truly,  
For **Piramal Pharma Limited**

**Tanya Sanish**  
Company Secretary

**Piramal Pharma Limited**

CIN: U24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000

[piramal.com](https://www.piramal.com)